CG Oncology, Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
CGON$72.64-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating Activities | ||
| Net loss | $(60,202) | $(34,452) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 841 | 24 |
| Stock-based compensation expense | 6,474 | 5,151 |
| Unrealized losses (gains) on short-term investments | 1,664 | (279) |
| Non-cash interest expense (income) | 46 | (176) |
| Non-cash lease expense | 13 | (14) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (8,066) | (546) |
| Accounts receivable, net | (587) | — |
| Inventory | 72 | — |
| Other assets | (998) | (35) |
| Accounts payable | 2,522 | 214 |
| Accrued expenses and other current liabilities | 1,607 | 836 |
| Other liabilities | (329) | — |
| Net cash used in operating activities | (56,943) | (29,277) |
| Investing Activities | ||
| Proceeds from sales and maturities of investments | 252,853 | 200,139 |
| Purchases of investments | (587,394) | (361,892) |
| Issuance of note receivable | — | (25,000) |
| Purchases of property and equipment | (304) | (16) |
| Net cash used in investing activities | (334,845) | (186,769) |
| Financing Activities | ||
| Proceeds from follow-on public offerings, net of issuance costs | 391,550 | — |
| Proceeds from exercise of common stock options | 1,669 | 682 |
| Withholding taxes paid on net exercise of stock options | (174) | — |
| Stock issuance costs | (47) | (232) |
| Net cash provided by financing activities | 392,998 | 450 |
| Net increase (decrease) in cash and cash equivalents | 1,210 | (215,596) |
| Cash and cash equivalents at beginning of period | 32,490 | 257,068 |
| Cash and cash equivalents at end of period | $33,700 | $41,472 |
| Supplemental Disclosure of Cash Flow Information | ||
| Cash paid for interest | $47 | $— |
| Cash paid for taxes | $— | $— |
| Non-cash Investing and Financing Activities: | ||
| Stock issuance costs, unpaid and accrued | $139 | $215 |
| Operating lease right-of-use asset obtained in exchange for lease liabilities | $791 | $859 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.